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Introduction: The identification of cell membrane-bound molecules with a
relevant role in cancer cell survival prompted the development of moAbs to
block the related pathways. In the last few years, the number of approved
moAbs for cancer treatment has constantly increased. Many of these drugs
significantly improved the survival outcomes in patients with solid tumours.
Areas covered: In this review, all the FDA-approved moAbs in solid tumours
have been described. This is an update of moAbs available for cancer treat-
ment nowadays in comparison with the moAbs approved until few years
ago. The moAbs under development are also discussed here.
Expert opinion: The research on cancer antigens as therapeutic targets led to
an expanding scenario of available treatment options in non-haematological
malignancies. In a few years, the number of approved drugs has increased
rapidly. Some of these agents are actually on label in combination with stan-
dard chemotherapy. Only some of them can be delivered as monotherapy.
The research on these new drugs is addressing both the identification of
further target molecules in key cancer-related pathways and the improve-
ment of drug effectiveness by changing the affinity and the selectivity of a
moAb relative to its target.
Keywords: cancer, cancer antigen, cytotoxic T-lymphocyte antigen 4, EGFR, HER2,
immunotherapy, moAbs, receptor activator of nuclear factor kB ligand, VEGF
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1. Introduction
The research on cancer immunology led to the development of moAbs targeting
specific tumour antigen. First these molecules were used with the aim of eliciting
an immunologic response against tumour cells. However, preclinical research
prompted the use of moAbs to target these oncogenic pathways, which start their
signalling through some molecules expressed on tumour cell surface.
Three years ago, we published a review about moAbs and antibody fragments in
solid tumours. In that paper, only four approved moAbs for the treatment of solid
tumours were reported [1]. Nowadays, the number of FDA-approved moAbs in
solid tumours has doubled. And even greater is the number of those moAbs in clin-
ical development for use in non-haematological malignancies. MoAbs have been
produced by different techniques, such as mouse ascites fluid and tissue cultures.
The application of recombinant DNA technology to hybridoma technology has
allowed production moAbs with greater safety and efficacy through chimerisation
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and humanisation. By this way, different forms of moAbs are
available including murine, human, chimeric and humanised
moAbs (Figure 1).
Generally, the use of moAbs aims to achieve various goals,
such as the blockade of oncogenic pathways with subsequent
effects on cell growth and apoptosis, the modulation of
immune response against tumour cells and more recently
moAbs conjugated with cytotoxic drugs used to be a vehicle
of these drugs to cancer cells [2-4].
Even though moAbs have been developed to be more
specific for tumour cells with respect to cytotoxic drugs, side
effects can arise during the treatment with moAbs [5,6]. These
adverse effects could be a consequence of the targeting of
receptors in normal cells or the activation of general immune
response.
Here, we review the moAbs approved for the clinical use in
non-haematological malignancies and also those that are
under development through the improvement of previous
strategies or the search for new targets. This paper could
represent an update of our previous paper [1] to show how
the scenario of moAbs use has been really expanding.
2. Actual FDA-approved moAbs for cancer
treatment
2.1 Anti-HER2 (trastuzumab, T-DM1, pertuzumab)
2.1.1 Trastuzumab
Human epidermal growth factor receptor 2 (HER2) is a
receptor of the EGFR family, which has been found to be
overexpressed in various tumour types but the most relevant
clinical implications are today well known for breast, gastric
and gastroesophageal junction cancers. HER2 protein overex-
pression found at immunohistochemistry (IHC) (IHC 3+) or
CerbB-2 gene amplification at fluorescence in situ hybridisa-
tion (FISH) are known to be negative prognostic factors and
a predictive for response to anti-HER2 drugs (trastuzumab,
lapatinib, pertuzumab) in patients with breast cancers: almost
15 -- 20% of them are HER2 positive [7]. Trastuzumab is a
humanised moAb directed against the extracellular domain
of the HER2/neu receptor. When this antibody binds its tar-
get, it inhibits the effect of the homodimerisation of
HER2 and the cleavage of the receptor with the consequent
blockade of the signal transduction cascade and inhibition of
the proliferation and survival of HER2-dependent tumours.
An antibody-dependent cell-mediated toxicity has been dem-
onstrated to be one of the possible mechanisms of action [8].
Trastuzumab has been approved for HER2-positive breast
cancer (in metastatic, neoadjuvant and adjuvant setting) and
for the treatment of locally advanced and metastatic gastric
and gastroesophageal junction cancer and its activity has
been evaluated with various chemotherapeutic drugs such as
taxanes and anthracyclines, platinum salts, fluorouracil, gem-
citabine and vinca alkaloids. The use of trastuzumab in
HER2-positive untreated metastatic patients showed a strong
improvement in terms of time-to-progression and overall sur-
vival (OS) when administered in combination with chemo-
therapy in a pivotal Phase III trial [9]. These results have
been confirmed by subsequent trials with taxanes [10,11] and
other chemotherapeutic agents [12-16]. Trastuzumab has also
been studied as monotherapy for metastatic breast cancer
patients but combination regimens showed greater results in
terms of responses [17]. Resistance to trastuzumab usually
occurs within 1 year after the start of treatment [18] but after
disease progression the continuation of trastuzumab in combi-
nation with a different subsequent chemotherapy regimen is a
possible valid strategy, suggested by some evidences [19,20].
Several studies in the adjuvant setting, enrolling > 10,000
patients, evaluated the addition of trastuzumab to
chemotherapy and in a meta-analysis of prospective trials,
the combination, compared with chemotherapy alone,
showed a significant benefit in terms of disease-free survival
(odds ratio [OR] = 0.69) and OS (OR = 0.78), with a reduc-
tion of local relapse by about 50% and distant recurrence near
to 40%. The improvements were demonstrated also when
trastuzumab, after the completion of chemotherapy was given
alone, in combination with taxanes following anthracyclines
plus cyclophosphamide and in combination with carboplatin
and docetaxel. These data confirmed the important role of
trastuzumab in the adjuvant setting for HER2-positive
patients with tumour diameter > 1 cm or metastatic lymph
nodes [21]. Data for patients with HER2-positive tumours
(£ 1 cm) and negative lymph nodes are today controversial.
Most of the studies, which evaluated the addition of trastuzu-
mab to chemotherapy as adjuvant treatment, also enrolled
node-negative patients but with tumours > 1 cm in diameter.
This category of patients obtained significant benefits from
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the addition of trastuzumab similar to those with late-stage
HER2-positive tumours [22,23]. There are no prospective
data for patients with HER2-positive node-negative and
< 1 cm tumours. Retrospective studies indicate that these
patients have a worse prognosis [24,25] (compared with those
with HER2-negative tumours and the same diameter) and
that they could benefit from the use of trastuzumab as adju-
vant therapy. Today, this benefit is not clear and data are
not always significant [26-28]. The duration of treatment with
trastuzumab in the adjuvant setting is still a topic of discus-
sion. At present, the duration of 1 year, after completion of
chemotherapy, represents the standard of care [22,29,30].
A recently approved indication of trastuzumab is for
HER2-positive metastatic gastric and esophagogastric junc-
tion tumours. In fact, ~ 20% of them overexpress HER2
and this represented the rationale to study trastuzumab in
these types of tumours [31]. The addition of trastuzumab
to HER2-positive gastric and gastroesophageal junction can-
cers, in a Phase III randomised trial (ToGA trial), showed
an improvement in OS for patients in the trastuzumab plus
chemotherapy arm versus chemotherapy alone (13.8 vs
11.1 months), obtaining a 26% of reduction of the death
rate. This improvement has been obtained only for patients
whose tumours were at IHC 3+ or IHC 2+ and FISH posi-
tive. No survival benefit has been shown in IHC 0 or 1+
and FISH-positive patients [32]. Trastuzumab is now a very
well-known drug, which has fully entered into the daily
clinical practice, both for breast cancer and for metastatic
gastric and esophagogastric junction cancers. It is a very
well-tolerated drug, with an excellent profile of toxicity, but
the only real limitation to its use is represented by cardiotox-
icity. For this reason, although some data regarding safety
with liposomal anthracyclines are available, the addition of
trastuzumab to standard anthracyclines is not recommended
[33,34].
2.1.2 T-DM1 (trastuzumab emtansine)
Trastuzumab-DM1 (trastuzumab emtansine) is an antibody--
drug conjugate composed of anti-HER2 moAb trastuzumab,
linked to an anti-microtubule agent DM1, which is a derivate
of maytansine [35]. The antitumour action of this drug is
related not only to the well-known role of trastuzumab, but
also to the inhibition of microtubular assembly induced by
DM1 on HER2-overexpressing cells. Indeed, trastuzumab
delivers DM1 to the targeted tumour cells, focusing its toxic-
ity almost only on cancer cells [36]. Moreover, it seems that
T-DM1 is internalised after binding cancer cells’ surface
receptors [37]. The drug has been approved in February
2013 by FDA for the treatment of HER2-positive metastatic
breast cancer patients who have received prior trastuzumab
and a taxane-based chemotherapy. After deriving promising
data from Phase I and II studies [36,38-40], it has been tested
in Phase III trials. In the EMILIA trial, a randomised
Phase III study, T-DM1 has been evaluated in comparison
with lapatinib plus capecitabine, in patients with HER2-pos-
itive locally advanced or metastatic breast cancer who had
prior received treatment with trastuzumab and taxane-based
chemotherapy. Nine hundred and ninety-one patients were
enrolled and primary end points were progression-free sur-
vival (PFS) and OS. Results showed an improvement both
in median PFS (9.6 vs 6.4 months; hazard ratio [HR]: 0.65;
95% CI: 0.55 -- 0.77; p = 0.001) and in median OS
(30.9 vs 25.1 months; HR: 0.68; 95% CI: 0.55 -- 0.85;
p = 0.001) for patients in the T-DM1 arm. A higher response
rate was seen in patients treated with T-DM1 (43.6 vs 30.8%;
p = 0.001) and its toxicity profile was better than the combi-
nation lapatinib plus capecitabine, with a grade 3 event rates
of 41 versus 57%, respectively [41]. These positive data are
particularly interesting as they were obtained in pre-treated
patients regardless of the number of previous treatments.
Moreover, a survival benefit was also seen in patients who
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Figure 1. Classification of moAbs according to the proportion of murine and human peptidic sequences.
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had disease progression within 6 months following the
completion of adjuvant or neoadjuvant treatment with trastu-
zumab. The MARIANNE trial, a randomised, three-arm
Phase III study, is evaluating efficacy and safety of T-DM1
with pertuzumab or without pertuzumab, versus the combi-
nation of trastuzumab plus taxanes in HER2-positive patients
with progressive or recurrent locally advanced or previously
untreated metastatic breast cancer and primary end point is
PFS. One thousand ninety-five patients have been enrolled
to date and results are awaited [42]. T-DM1 has been tested,
in the TH3RESA study, in comparison with treatment of
the physician’s choice in patients with metastatic or unresect-
able locally advanced/recurrent HER2-positive breast cancer,
who have been treated at least with two prior HER2-directed
therapies. Co-primary outcome measures of this Phase III trial
are PFS and OS in the intention-to-treat population. In
February 2013, 602 patients were enrolled and the 75% of
them had visceral disease. Patients had received a median of
four prior regimens for the advanced disease. Results showed
an improvement in median PFS of almost 3 months for
patients receiving T-DM1 (6.2 vs 3.3 months; HR:0.528;
95% CI: 0.422-0.661; p < 0.0001) while statistically signifi-
cant data for OS had not yet been reached, although the
interim analysis showed a positive trend for T-DM1 arm.
Objective responses also improved for T-DM1 patients with
a consistent difference (31.3 vs 8.6%; p < 0.001) and crossing
over from the control to the experimental arm was permitted
after progression. Serious adverse events were fewer in the T-
DM1 arm than in the treatment of the physician’s choice
one [43]. These data, as already pointed out by the EMILIA
trial and previous studies, confirm the great importance of
T-DM1 in the panorama of treatments for patients with
HER2-positive metastatic breast cancer.
2.1.3 Pertuzumab
Pertuzumab is a fully humanised moAb directed against the
extracellular dimerisation domain II of HER2. It binds a
different epitope of the HER2 receptor from the one targeted
by trastuzumab [44]. In fact, trastuzumab and pertuzumab
work with a complementary action because the first inhibits
ligand-independent HER2 signalling without preventing
ligand-activated HER2/HER3 or HER2/HER1 heterodimer-
isation, whereas pertuzumab prevents the formation of homo-
and heterodimers of HER2 with the other EGFRs, including
HER1, HER3 and HER4. Both in vitro and in vivo prelimi-
nary evidences of trastuzumab’s and pertuzumab’s synergic
actions have been available for some years and these data
were conducted to test the two drugs together for clinical
use [45,46]. Pertuzumab was the first drug approved by FDA
in 2012, with the indication of first-line treatment in combi-
nation with trastuzumab and docetaxel for patients with
HER2-positive metastatic breast cancer naı¨ve to any anti-
HER2 therapy or chemotherapy for metastatic disease on
the basis of the CLEOPATRA study. In this trial, 808 patients
with HER2-positive metastatic breast cancer were randomised
to receive a combination of trastuzumab and docetaxel with
either placebo or pertuzumab as first-line treatment [47]. The
study met its primary end point with an improvement of
6 months in PFS for patients in the pertuzumab arm
(18.5 vs 12.4 months; HR: 0.62; 95% CI: 0.51 to 0.75;
p < 0.001. A further analysis showed a significant benefit
also in OS for patients allocated in the pertuzumab group,
although it had not been reached at the time of the analysis
(95% CI: 42.4--not available) and no differences in cardio-
toxic effects were seen between the two groups [48,49]. In Sep-
tember 2013, a second indication was approved for
pertuzumab on the basis of the results shown by the
Phase II NeoSphere trial, in which 417 chemo-naı¨ve patients
with HER2-positive early-stage breast cancer were rando-
mised in four arms to receive: trastuzumab plus docetaxel
(n = 107, group A), pertuzumab and trastuzumab plus doce-
taxel (n = 107, group B), pertuzumab plus trastuzumab
(n = 107, group C) or pertuzumab plus docetaxel (n = 96,
group D), with pathological complete response in the breast
as primary end point. Pertuzumab was administered at the
loading dose of 840 mg, followed by 420 mg every 3 weeks,
trastuzumab first at 8 mg/kg loading dose, followed by
6 mg/kg every 3 weeks and docetaxel in the group A 75 mg/
m2, escalating, if tolerated, to 100 mg/m2 every 3 weeks.
Patients in the pertuzumab and trastuzumab plus docetaxel
showed a higher complete response rate (pCR: 45.8; 95%
CI: 36.1 -- 55.7) compared with that obtained in the trastuzu-
mab plus docetaxel group (pCR: 29; 95% CI: 20.6 -- 38.5).
Results were inferior in the pertuzumab plus docetaxel arm
(pCR: 24; 95% CI: 15.8 -- 33.7) and in the pertuzumab
plus trastuzumab group (pCR: 16.8; 95% CI: 10.3 -- 25.3).
The rates of severe adverse events were similar across the
groups A, B and D, but obviously lower in group C [50].
This approval was supported also by the results of another
Phase II study: the TRYPHAENA trial. This study was con-
ducted to assess the toxicity of the anti-HER2 therapy with
anthracyclines and carboplatin in patients with localised,
inflammatory or early (2 cm tumour size or lymph node-pos-
itive) HER2-positive breast cancer. Patients were treated with
anthracycline-containing chemotherapy administered with
sequential or concurrent trastuzumab and pertuzumab or
with carboplatin and docetaxel in addition to concurrent tras-
tuzumab and pertuzumab. The highest pCR rate was
obtained with the carboplatin-docetaxel regimen plus trastu-
zumab and pertuzumab (66%). The addition of trastuzumab
and pertuzumab to chemotherapy resulted in low rates of
symptomatic left ventricular systolic dysfunction [51]. For
these reasons, in the neoadjuvant setting, pertuzumab has to
be administered at the initial loading dose of 840 mg in a
60 min infusion followed by a continuation dose of 420 mg
intravenously (i.v.) as a 30 -- 60 min infusion repeated every
21 days for three or six cycles in addition to chemotherapy:
for four preoperative cycles in combination with docetaxel
and trastuzumab followed by three cycles of fluorouracil, epi-
rubicin and cyclophosphamide (FEC), for three preoperative
G. Bronte et al.
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cycles in combination with docetaxel and trastuzumab after
three FEC or for six preoperative cycles with docetaxel, carbo-
platin and trastuzumab.
2.2 Anti-EGFR (cetuximab, panitumumab)
EGFR represents today one of the most important targets for
cancer therapy, especially for the treatment of metastatic
colorectal cancer (mCRC) and head and neck cancers. Two
moAbs directed against EGFR are available for cancer ther-
apy: cetuximab and panitumumab. Cetuximab is a chimeric
moAb that binds the extracellular domain of EGFR blocking
its activation normally provided by EGF [52,53].
The drug has been approved by FDA in 2004 for the treat-
ment of EGFR-expressing, mCRC in combination with irino-
tecan on the basis of the results of the BOND trial [54]. The
EPIC trial confirmed the promising activity of cetuximab
showing an advantage in terms of time-to-progression and
response rate with the addition of the drug with irinotecan
compared with irinotecan alone for mCRC patients after
progression on 5-fluorouracil (5-FU) and oxaliplatin chemo-
therapy. No differences in OS were demonstrated probably
for the great number of patients in the irinotecan arm who
received cetuximab and irinotecan at progression [55]. In the
CRYSTAL study, the addition of cetuximab to FOLFIRI pro-
duced positive results in terms of response rate (RR), PFS and
OS, but these benefits were limited to KRAS wild-type
patients. Moreover, the presence of BRAFV600E mutation con-
ferred a poorer prognosis in both the arms [56-58]. The positive
results in terms of PFS of the combination of cetuximab with
oxaliplatin-based chemotherapy in the OPUS trial, in KRAS
wild-type patients, led to the approval of cetuximab as first-
line treatment in EGFR-expressing and KRAS wild-type
mCRC patients [59]. In contrast to these data, both in the
COIN and the Nordic FLOX trial the addition of cetuximab
to either FOLFOX/Capecitabine plus oxaliplatin (CAPOX)
(MRC COIN) or oxaliplatin plus a fluoro-pyrimidine
(FLOX) (NordicFLOX) did not demonstrate a significant
improvement in either OS or PFS. A deeper analysis of the
COIN study showed differences between the results obtained
with the use of i.v. 5-FU or capecitabine in combination with
oxaliplatin and cetuximab, and particularly bad data emerged
when cetuximab and oxaliplatin were associated with capeci-
tabine. Moreover, the bolus administration of 5-FU provided
in the NORDIC trial seems to have a detrimental effect with
the addition of oxaliplatin and cetuximab [60,61]. Recently, a
rechallenge with cetuximab in pre-treated mCRC patients
have shown a further benefit. By this finding, a model
for the development of resistance to cetuximab has been
proposed [62].
The improvements in OS obtained with the addition of
cetuximab to radiotherapy compared with radiotherapy alone
in a Phase III randomised trial led to FDA approval of cetux-
imab for head and neck cancers for use in combination with
radiation therapy for the treatment of locally or regionally
advanced squamous cell carcinoma and as a single agent for
the treatment of patients with recurrent or metastatic squa-
mous cell carcinoma of the head and neck after platinum-
based therapy failure [63]. Finally, on the basis of the positive
results of a Phase III trial, FDA approved the use of cetuximab
in combination with platinum- and 5-FU-based chemother-
apy as first-line therapy for recurrent or metastatic patients
affected by squamous cell carcinoma of the head and neck [64].
The second moAb available for the treatment of mCRC is
panitumumab, a fully human moAb approved in 2006 for
patients with EGFR-expressing mCRC after progression or
following fluoropyrimidine-, oxaliplatin- and irinotecan-
containing regimens. The efficacy of the drug in monotherapy
has been demonstrated in comparison with best supportive
care (BSC) in 463 mCRC patients refractory to 5-FU, irino-
tecan and oxaliplatin. In this trial, although no improvement
in OS was obtained, panitumumab provided a significant
benefit in RR (10 vs 0%; p < 0.001) and PFS at 8 weeks
(49 vs 30%; p < 0.001) and further analysis confined these
benefits to KRAS wild-type patients [65,66]. The use of panitu-
mumab as first-line treatment in addition to FOLFOX che-
motherapy has been evaluated in the randomised PRIME
trial, the results of which showed an improvement both in
median PFS for KRAS wild-type mCRC patients treated
with panitumumab plus chemotherapy (10 vs 8.6 months;
HR: 0.80; p = 0.01) and in median OS (23.9 vs 19.7 months;
HR: 0.88; p = 0.17) [67]. A recent retrospective analysis con-
ducted on the samples of the PRIME trial demonstrated
that other KRAS mutations in exons 3 and 4 (in addition to
the well-known exon 2 mutations) and NRAS mutations (on
exons 2, 3 and 4) can determine resistance to panitumumab
and that the use of the drug is associated with a detrimental
effect in mutated patients [68]. On the basis of these criteria,
the use of panitumumab is approved only for RAS (KRAS
and NRAS) wild-type mCRC patients. Moreover, a retrospec-
tive analysis of the OPUS trial led to similar conclusions when
patients with mutations in exons 2, 3 and 4 of NRAS and in
exons 3 and 4 of KRAS were excluded from the exon 2
KRAS wild-type population. For these reasons, the limitation
of the use of panitumumab in KRAS and NRAS wild-type
patients has been extended also to the use of cetuximab. In
the second-line setting, panitumumab has been tested in com-
bination with FOLIFIRI versus FOLFIRI alone in KRAS
wild-type patients. This trial demonstrated an improvement
in PFS for patients treated with the combination (6.7 vs
4.9 months; HR: 0.82; p = 0.0023) and a trend toward longer
OS but without statistical significance [69]. The need for a
more precise selection of mCRC patient candidates for anti-
EGFR treatment has been confirmed by the analysis of the
results of the FIRE-3 trial, in which 592 KRAS wild-type
mCRC patients were randomised to receive FOLFIRI plus
either cetuximab or bevacizumab as first-line treatment. The
results showed an improvement in median OS of almost
4 months in the cetuximab arm but no benefit in terms of
overall response rate (ORR) and PFS was observed when con-
sidering only exon 2 KRAS wild-type tumours [70]. Moreover,
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an updated analysis of the Phase III CRYSTAL study, pre-
sented at the 2014 American Society of Clinical Oncology
(ASCO) Annual Meeting by Professor Ciardiello, demon-
strates that the addition of cetuximab to FOLFIRI as the
first-line treatment in mCRC provides a significant benefit
across all end points in RAS wild-type (KRAS and NRAS
wild-type) patients, whereas in patients with any tumour
with RAS mutation, no benefit was found [71].
2.3 Anti-VEGF (bevacizumab)
Bevacizumab, another cornerstone of anticancer therapy, is a
humanised moAb that inhibits angiogenesis through the bind-
ing of VEGF, which is one the most important mediators of
neo-angiogenesis and tumour growth. The development of a
new tumour vascularisation mediated by VEGF and other
growth factors induced through the hypoxia-inducible
transcription factor is in fact considered a key target to inhibit
tumour proliferation [72,73]. Although four different isoforms
of VEGF have been identified (VEGF-A, -B, -C, -D),
VEGF-A is considered the most important and its functions
are mediated by the interaction with VEGF receptors
(VEGFR1 or Flt-1, and VEGFR2 or KDR) [74,75]. Bevacizu-
mab is able to bind all isoforms of VEGF preventing the inter-
action with its receptors and their subsequent activation [76]. It
has also been demonstrated that VEGFR inhibition mediated
by bevacizumab on cancer cells induces a regression of abnor-
mal tumour vascularisation with the normalisation of the vas-
cular bed and the inhibition of neo-angiogenesis [77]. The
most common adverse events related to bevacizumab showed
in all clinical trials are hypertension, bleeding and proteinuria.
Although a frequent blood pressure control is recommended,
hypertension is often manageable with oral antihypertensives.
During the last 10 years, bevacizumab has been studied for
various diseases reaching many indications for solid cancers
such as mCRC, metastatic breast cancer, metastatic renal cell
carcinoma, metastatic ovarian cancer, advanced NSCLC and
glioblastoma. After first approval of bevacizumab as first-line
treatment for patients with mCRC in 2004 on the basis of
previous positive studies with both 5-FU/leucovorin in a
Phase II trial [78] and with IFL-Saltz regimen [79], other trials
evaluated the role of bevacizumab in addition to oxaliplatin-
based regimens as first-line treatment of mCRC or in addition
to capecitabine monotherapy, but they did not reach the same
statistical significance [80]. To date, bevacizumab is approved
as first- and second-line treatment of mCRC patients in
addition to 5-fluorouracil-irinotecan- or 5-fluorouracil-oxali-
platin-based chemotherapy [81-83]. In 2013, FDA approved
bevacizumab in combination with fluoropyrimidine-irinote-
can- or fluoropyrimidine-oxaliplatin-based chemotherapy for
the treatment of patients whose disease has progressed during
the first-line treatment with a bevacizumab-containing regi-
men. The rationale of ‘bevacizumab beyond progression’
came from the results of the ML18147 Phase III trial, in which
820 patients previously treated with bevacizumab-containing
regimens were randomised to receive chemotherapy alone
(n = 411) or chemotherapy in combination with bevacizumab
(n = 409). Then bevacizumab was administered until disease
progression or unacceptable toxicity. The addition of bevacizu-
mab to chemotherapy provided a small but statistically signif-
icant improvement in median OS (11.2 vs 9.8 months; HR:
0.81; p = 0·0062) [84]. A subsequent analysis of the trial con-
firmed these positive data, which seem to be independent of
the KRAS status [85]. Recently at the 2014 ASCO Annual
Meeting, data about an alternative schedule of association of
bevacizumab have been presented. The TRIBE trial evaluated
efficacy and toxic impact of the addition of bevacizumab
with FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin
and irinotecan) chemotherapy as first-line treatment of
mCRC patients. This study demonstrated improvements in
median PFS and median OS with FOLFIRI + bevacizumab
versus FOLFIRI + bevacizumab independently of RAS and
BRAF status, with a trend toward a larger benefit in BRAF-
mutated patients limited by small number of patients. This
intensive treatment is also more toxic than standard treatments
and is not suitable for all patients; it could be a good therapeu-
tic option for a selected category of young and fit patients [86].
In 2006, on the basis of a large Phase III trial, the use of
bevacizumab was approved as first-line therapy in combina-
tion with chemotherapy for patients with unresectable, locally
advanced, recurrent or metastatic, non-squamous, NSCLC
[87]. This limitation is linked to the higher risk of hemoptoe
for squamous NSCLCs, which usually presents cavitated
lesions involving the main bronchus and mediastinum great
vessels as demonstrated by clinical trials [88]. These positive
data of efficacy have been confirmed in the AVAiL trial,
in which bevacizumab was administered with different
platinum-based chemotherapy (cisplatin plus gemcitabine)
in patients with stage IIIB/IV NSCLC [89]. The use of bevaci-
zumab as first-line therapy for HER2-negative metastatic
breast cancer patients in combination with paclitaxel received
a rapid approval in 2008 on the basis of the positive data in
terms of PFS and ORR in the interim analysis of the
Phase III E2100 trial [90], but this accelerated approval was
revoked in 2011 by FDA on the basis of the lack of benefit
in OS in two subsequent trials: AVADO and RIBBON-1
[91,92]. Despite these conflicting data and the withdrawal of
indication by the FDA, the European Medicines Agency
(EMA) has still maintained bevacizumab’s approval for
HER2-negative metastatic breast cancer patients.
In 2009, FDA approved the use of bevacizumab in combi-
nation with IFN-a for the treatment of patients with meta-
static renal cell carcinoma on the basis of the results of two
randomised trials, which demonstrated advantages in terms
of median PFS and ORR [93,94], whereas no benefit in OS
was found [95]. In 2009, bevacizumab received another rapid
approval as a single-agent treatment for patients with glioblas-
toma, after progression following prior therapy, on the basis
of the positive data of two trials. In a Phase II trial (BRAIN),
167 patients were randomised to receive bevacizumab alone
or bevacizumab in combination with irinotecan. Objective
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response rates were 28.2% for bevacizumab and 37.8% for the
combination arm, respectively. Median 6-month survival was
42.6% for bevacizumab and 50.3% for the combination arm
and median OS was 9.2 and 8.7 months, respectively [96].
These results have been confirmed by a NCI Phase II study,
in which 48 heavily pre-treated patients with recurrent glio-
blastoma have been treated with bevacizumab monotherapy
and have received irinotecan in combination after disease pro-
gression. The study showed a 6-month PFS of 29% with a
median OS of 31 weeks and a 35% of objective responses [97].
EMA did not approve this indication of bevacizumab probably
for the lack of consistent data. The results of two randomised
trials have led to the European approval of bevacizumab for
the treatment of advanced ovarian cancer. In these two studies
(GOG218 and ICON7), the addition of bevacizumab to stan-
dard carboplatin-paclitaxel chemotherapy followed by bevaci-
zumab maintenance has been compared with chemotherapy
alone obtaining an improvement in PFS (18.2 vs 12.7 months
in the GOG0218, 18.3 vs 16.0 in the ICON7) [98]. In the
planned final analysis of the ICON7 trial, presented at the
2013 European Cancer Congress, a 4.8-month benefit in OS
was demonstrated in patients with bad prognosis and treated
with bevacizumab plus chemotherapy [99].
2.4 Anti-VEGFR (ramucirumab, aflibercept)
Ramucirumab is a new human recombinant moAb of the
IgG1 class that binds to VEGFR2 and blocks the activation
of the receptor. It has been recently approved by FDA as
single agent for the treatment of patients with advanced or
metastatic gastric or gastroesophageal junction adenocarci-
noma with disease progression on or after prior treatment
with fluoropyrimidine- or platinum-containing chemother-
apy. This approval was supported by the positive results of
the two randomised, Phase III, REGARD and RAINBOW
studies, comparing respectively ramucirumab plus BSC versus
placebo plus BSC, and ramucirumab in combination with
paclitaxel versus paclitaxel plus BSC, in patients with pre-
treated advanced gastric or gastroesophageal junction adeno-
carcinoma. Both these trials have shown that the addiction
of ramucirumab significantly improved the patients’ survival
outcomes: OS (REGARD: 5.2 vs 3.8 months; HR: 0.776;
RAIMBOW: 9.63 vs 7.36 months; HR: 0.87) and PFS
(REGARD: 2.1 vs 1.3 months; HR: 0.483; RAIMBOW:
4.40 vs 2.86 months; HR: 0.635) [100,101], with an acceptable
toxicity profile. The most common adverse events observed in
ramucirumab-treated patients were hypertension and diar-
rhoea. The grade 3 -- 4 adverse reactions included hyperten-
sion and hyponatremia. This new moAb is also under
clinical investigation in several Phase III trials of colorectal
cancer (NCT01183780), hepatocellular carcinoma (NCT0
1140347), NSCLC (NCT01168973) and breast cancer
(NCT00703326). Promising results from these studies are
expected within the end of 2014.
Aflibercept is a fusion protein consisting of portions of
human VEGFR1 -- 2 extracellular domains fused to the
crystallisable fragment portion of human IgG1, produced by
recombinant DNA technology. Although it is not an antibody
itself, it deserves to be mentioned among the new approved
treatments targeting the angiogenesis process. It has been eval-
uated in combination with irinotecan-based chemotherapy in
a Phase III randomised study in patients with mCRC refrac-
tory to oxaliplatin-based chemotherapy. The addition of
aflibercept to FOLFIRI regimen significantly improved OS
(13.5 vs 12.06 months; HR: 0.817), PFS (6.90 vs 4.67
months; HR: 0.758) and RR (19.8 vs 11.1%: p = 0.0001),
with an acceptable toxicity profile [102]. The positive results
of the VELOUR trial led to the clinical approval of aflibercept
as the second-line therapy in patients with mCRC, who have
progressed to an oxaliplatin-based first-line therapy indepen-
dent from prior use of bevacizumab.
2.5 Anti-CTLA-4 (ipilimumab)
In 2011, ipilimumab was approved by the FDA for the
treatment of patients with unresectable or metastatic mela-
noma, who had previously been treated with standard
chemotherapy. Ipilimumab is a fully human moAb directed
against CTLA-4 receptor, which is located on the surface of
activated T lymphocytes. Normally, the interaction between
CTLA-4 and its ligands (CD80/CD86), expressed on anti-
gen-presenting cells, produces an inhibitory signal within the
lymphocyte contributing to the homeostatic regulation of
the immune response. Ipilimumab binds CTLA-4, thus block-
ing its activation and finally producing an immune-stimulat-
ing effect on T lymphocytes [103]. Ipilimumab approval was
based on the results of a randomised three-arm Phase III
trial, in which pre-treated 676 patients with advanced mela-
noma were randomised to receive ipilimumab at the dose of
3 mg/kg in combination with a gp100 peptide vaccine
(n = 403), or ipilimumab 3 mg/kg plus placebo (n = 137), or
only gp100 vaccine (n = 136). Median OS was significantly
longer for patients treated with ipilimumab alone (10.1 vs
6.4 months; HR: 0.66; p = 0.003) or administered in combina-
tion with gp100 (10.0 vs 6.4 months; HR: 0.68; p < 0.001)
compared with patients treated with gp100 alone. In this
study, almost 15% of the patients showed grade 3 and 4 adverse
events and the most frequent immune-related adverse event
was diarrhoea. Seven immune-related deaths were regis-
tered [104]. A second Phase III trial evaluated ipilimumab in
502 previously untreated patients with metastatic melanoma.
Patients were randomised to receive ipilimumab (10 mg/kg
every 21 days for four times as induction, and then 10 mg/kg
every 3 months in maintenance) in combination with dacarba-
zine or dacarbazine plus placebo. The primary end point of the
study was achieved with a significant improvement in OS for
patients receiving ipilimumab plus dacarbazine (11.2 vs
9.1 months; HR: 0.72; p < 0.001) and with a higher 3-year sur-
vival rate (20.8 vs 12.2%). The combination of dacarbazine
with ipilimumab increased liver toxicity and grade
3 -- 4 adverse events occurred in 56.3% of the patients in the
ipilimumab plus dacarbazine group. No toxic death was
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registered [105]. A promising field of research on ipilimumab is
represented by lung cancer [106,107]. Two Phase III trials have
evaluated ipilimumab in both advanced NSCLC [108] and
extensive-stage SCLC [109], showing very promising results.
2.6 Anti-receptor activator of nuclear factor kappaB
ligand (denosumab)
One of the most frequent sites of metastasis of solid tumours
is the bone and the presence of bone metastasis, although
often not considered a life-threatening condition, modifies
greatly patients’ quality of life and prognosis because it may
cause complications such as fractures, severe pain, nerve com-
pression and hypercalcaemia. Malignant cells derived from
the primary tumour once located in the bone are able to
induce the production by osteoblasts of receptor activator of
nuclear factor kB ligand (RANKL) through the secretion of
many cytokines and growth factors. The interaction between
RANKL and its receptor RANK leads to an osteoclastic acti-
vation and thus to a disequilibrium between bone formation
and resorption [110]. Denosumab is a fully human moAb
that binds with high affinity Rank-ligand (RANKL) prevent-
ing its interaction with RANK. The decreased availability of
complex RANKL/RANK reduces the number and functions
of osteoclasts, decreasing bone resorption and destruction
induced by malignant cells. It was approved by FDA in
2010 for the prevention of skeletal-related events in patients
with bone metastases from solid tumours on the basis of three
randomised trials in which denosumab, administered subcuta-
neously at the dose of 120 every 4 weeks, has been compared
with zoledronic acid 4 mg administered i.v. every 4 weeks. In
these studies, patients previously treated with i.v. bisphospho-
nate and with reduced renal function (creatinine clearances
< 30 ml/min) were excluded. In all these trials, denosumab
resulted superior to zoledronic acid in preventing or delaying
skeletal complications in patients with advanced malignancies
and bone metastases, although no improvement in OS was
observed. The most severe clinical problems linked to denosu-
mab and highlighted by the cited studies are: hypocalcaemia
and osteonecrosis of the jaw, which occurred in a higher
percentage of patients treated with denosumab (3.1%) than
those treated with zoledronic acid (1.3%) [111]. For these rea-
sons, it is mandatory to perform an oral examination before
starting denosumab and to administer an adequate supple-
ment of calcium and vitamin D to all candidate patients. In
another randomised, Phase III, placebo-controlled trial, deno-
sumab was studied to evaluate if the treatment of patients
with non-metastatic castration-resistant prostate cancer could
prevent or delay the occurrence of bone metastasis. Results
showed that denosumab significantly prolonged bone metas-
tasis-free survival compared with placebo (29.5 vs 25.2
months; HR: 0.85; p = 0.028) and delayed time to first
bone metastasis (33.2 vs 29.5 months; HR: 0.84;
p = 0.032), whereas no improvement in OS was obtained [112].
These interesting data suggest that although not providing
benefits in terms of survival, the use of drugs that target the
bone microenvironment through RANK functions could cre-
ate hostile conditions for the development of bone metastasis.
Finally, on 24 July 2014, denosumab received an extended
indication from the EMA Committee for Medicinal Products
for Human Use, concerning the treatment of adults and skel-
etally mature adolescents with giant cell tumour of bone that
is unresectable or where surgical resection is likely to result in
severe morbidity.
3. MoAbs under clinical development
Since the approval of the first moAb, hundreds of moAbs,
including murine, chimeric and humanised antibodies, have
been developed for cancer treatment. As reported here, some
of these have been approved by FDA and are already available
for clinical use in everyday practice, as monotherapy or in
combination with standard chemotherapy regimens. How-
ever, most are actually under investigation in clinical trials,
often in early clinical development (Table 1). Some of these
new moAbs focus on molecular pathways, which have already
been known to be related to cancer development and progres-
sion, trying to improve the efficacy of the available treatments.
Other moAbs target the new emerging molecular pathways,
which seem to be involved in carcinogenesis.
3.1 The improvement of previous strategies
Among the moAbs that are actually undergoing evaluation as
cancer treatment in Phase III clinical studies, necitumumab, a
recombinant human anti-EGFR moAb, which was designed
to block the ligand binding site of the human EGFR was
investigated in two randomised Phase III trials on NSCLC.
The Phase III SQUIRE trial of gemcitabine--cisplatin chemo-
therapy plus necitumumab versus gemcitabine--cisplatin
chemotherapy alone in the first-line treatment of patients
with stage IV squamous NSCLC has been recently completed,
showing that the addition of necitumumab to chemotherapy
statistically significantly improved OS (HR: 0.84;
p = 0.012) and PFS (HR: 0.85; p = 0.020) [113]. Otherwise,
the randomised Phase III trial (INSPIRE) of necitumumab
plus cisplatinum--pemetrexed versus cisplatin--pemetrexed
alone, as first-line therapy, in stage IV non-squamous
NSCLC, did not meet its primary end point (PFS: 5.6 vs
5.6 months; HR: 0.96), resulting in a higher frequency of
grade ‡ 3 adverse events (skin reaction, gastrointestinal reac-
tion, asthenia, etc.) [114]. Tremelimumab is an investigational,
fully human moAb directed against CTLA-4, a co-inhibitory
receptor that represses effector T-cell activity in cancer. On
the basis of promising responses observed in early clinical
trials, a Phase III trial compared tremelimumab monotherapy
versus standard chemotherapy as first-line therapy for
advanced melanoma patients. Unfortunately, the study was
stopped early, because no significant survival differences
were observed between the two treatment arms [115]. Tremeli-
mumab is also undergoing clinical investigation in several
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Phase II trials of mesothelioma (NCT01843374), colorectal
cancer (NCT00313794) and hepatocellular carcinoma
(NCT01008358).
3.2 The search for new targets
Following the success of ipilimumab in the clinic, new antibod-
ies against the immune-checkpoints inhibitors have been devel-
oped. The anti-programmed cell death 1 (PD-1) (nivolumab)
and anti-programmed cell death-ligand 1 (PD-L1) (MPDL
3280A) are the two moAbs in the most advanced phases of
clinical investigation. Both the new moAbs have shown a great
activity in early clinical trials, showing great, durable responses
in a variety of solid tumours, including NSCLC, castration-
resistant prostate cancer, renal cell carcinoma, melanoma,
CRC and gastric cancer [116,117]. On the basis of these promising
results, nivolumab is actually undergoing clinical evaluation in
several Phase III randomised trials, both as single agent, and
in combination with other target therapies or chemotherapies,
in NSCLC (NCT02041533, NCT01642004, NCT0167
3867), melanoma (NCT01721772, NCT01721746, NCT01
844505) and renal-cell carcinoma (NCT01668784). MPDL
3280A is also under investigation in a randomised Phase III
trial comparing anti-PD-L1 with docetaxel in patients with
advanced NSCLC who have failed platinum therapy (NCT0
2008227). MetMab (onartuzumab) and AMG-102 (rilotumu-
mab) are the two anti-cMet moAbs currently most advanced in
clinical development. Onartuzumab is a humanised, monova-
lent antibody that blocks the ligand-binding site of the
hepatocyte growth factor receptor, thereby inhibiting the
MET dimerisation and the downstream signalling pathways.
Despite the promising results of the randomised Phase II
study [118], the subsequent Phase III trials did not confirm the
efficacy results, showing that the addition of onartuzumab to
erlotinib did not improve OS (HR: 1.27; p = 0.068; median
OS: 6.8 vs 9.1 months), PFS (HR: 0.99; p = 0.92; median
PFS: 2.7 vs 2.6 months) or ORR (8.4 vs 9.6%; p = 0.63)
[119]. Rilotumumab is a fully human moAb targeting human
hepatocyte growth factor/scatter factor (HGF/SF), which
inhibits the binding of HGF/SF to its receptor MET. Rilotu-
mumab is undergoing clinical evaluation in a Phase III,
randomised, placebo-controlled study, in combination with
epirubicin, cisplatin and capecitabine as first-line therapy, in
advanced, MET-positive, gastric or gastroesophageal junction
adenocarcinoma (NCT01697072). Unfortunately, negative
results emerged from the randomised, Phase III study of farletu-
zumab, a humanised moAb targeting human folate receptor,
in combination with carboplatin and a taxane in patients
with platinum-sensitive epithelial ovarian cancer, in first relapse
(NCT008 49667). The study did not meet its primary end
point PFS, but the drug is actually undergoing clinical investi-
gation in lung cancer (NCT01218516). Finally, racotumomab
is a murine moAb that mimics NGcGM3 ganglioside, highly
expressed on the cell surface of several human cancers, including
lung, breast, melanocytes and colon. Therefore, it acts as a
therapeutic vaccine, triggering a specific immune response of
the patient’s immune system, against this specific target. A
randomised, Phase III trial is ongoing, evaluating the efficacy
and safety of active specific immunotherapy with racotumomab
plus BSC versus BSC in patients with advanced NSCLC, who
have not progressed during the standard first-line treatment
(NCT01460472).
4. Conclusion
Since 3 years ago, the approval of moAbs for the treatment
of non-haematological tumours has expanded rapidly.
Nowadays, the number of moAbs approved for this label
has doubled. These molecules can be grouped into five types:
anti-HER2, anti-EGFR, anti-VEGF, anti-CTLA-4 and
anti-RANKL.
All these drugs are supported by a solid basis of scientific
evidences from clinical trials. The mechanisms of action, the
outcomes and the toxicity profiles of these drugs are discussed
here. Most of these moAbs achieved significant improvement
of overall survival by the combination with standard
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chemotherapy, that is, trastuzumab, pertuzumab, cetuximab,
panitumumab, bevacizumab, ramucirumab and aflibercept.
The other moAbs are delivered as monotherapy, that is, T-
DM1, ipilimumab and denosumab (Table 2). For some of
the approved moAbs, predictive biomarkers are available for
the selection of those patients who could achieve the best
outcomes. These biomarkers include RAS mutations for
anti-EGFR moAbs in mCRC patients and HER2 expression
for anti-HER2 moAbs in breast cancer patients. This review
can provide a summary of new data available for all FDA-
approved moAbs patients with solid tumours.
5. Expert opinion
This update shows that the research on moAbs targeting can-
cer, namely solid malignancies, is very rapid. These moAbs
allow targeting both the key pathways of cancer cell survival
and the molecules produced by stromal cells and immune
cells in tumour microenvironment. These mechanisms of
action led to an improvement of overall survival in compari-
son with the use of standard chemotherapy only.
Originally, there was a great expectation from these tar-
geted drugs, which were deemed ‘magic bullets’ to definitively
defeat cancer without the chemotherapy-related life-threaten-
ing toxicity. Nowadays, we know that the goals obtained by
these moAbs are less striking than expected. Indeed, some of
these drugs allowed an improvement of survival outcomes
by just few months. This goal is not always clinically relevant
even though statistically significant. In the meantime, the
introduction of these moAbs into the clinical practice consis-
tently increased the total outlay for cancer treatment.
This effect implies that not all the healthcare systems of
various countries can afford these increasing costs, although
FDA and other regulatory agencies approve these drugs on
the basis of the scientific evidences from clinical trials. For
these reasons, the applicability of new treatments in clinical
practice has to be validated also on the basis of pharmacoeco-
nomic analyses. The approval of further moAbs should be
taken into account if their use is really affordable by health-
care systems.
The research on moAbs for solid malignancies is now
addressing new targets. And also new approaches have been
developed, such as the combination of a moAb with a cyto-
toxic drug in the same molecule. This strategy allows to
make easier the delivery of a cancer treatment with the
concomitant improvement of efficacy and the reduction of
toxicity rates in comparison with the standard combination
of a chemotherapy regimen together with a moAb.
The study of this kind of strategies would be optimised by
the evaluation of targeted action on tumour tissue through
molecular imaging, that is, positron-emission tomography.
A similar result could be offered by the application of liquid
Table 2. Approved moAbs in advanced solid tumours.
Targets moAbs Solid tumours Setting OS (months) Ref.







BC 1-line N.A. [91,92]
OC 1-line 39.3* [99]
Glioblastoma Pre-treated pts. 9.2 [96]
RCC 1-line N.A. [95]
NSCLC 1-line 12.3 [87]
VEGFR2 Ramucirumab GC 2-line 5.2
9.63
[100,101]
VEGFR1/2 Aflibercept CRC 2-line 13.5 [102]













HER2 Trastuzumab HER2+ BC 1-line 31.2 [10]
HER2+ GC 1-line 13.8 [32]
T-DM1 HER2+ BC Pre-treated pts. 30.9 [41]
Pertuzumab HER2+ BC 1-line N.A. [49]
CTLA-4 Ipilimumab Melanoma Unresectable or metastatic 10.1
11.2
[104,105]
RANKL Denosumab Bone metastases - N.A. [111]
*Poor prognosis pts.
BC: Breast cancer; CRC: Colorectal cancer; CT: Chemotherapy; GC: Gastric cancer; CTLA-4: Cytotoxic T-lymphocyte antigen 4; H&N: Head and neck cancer;
N.A: Not available; OC: Ovarian cancer; pts: Patients; RANKL: Receptor activator of nuclear factor kB ligand; RCC: Renal cell carcinoma; RT: Radiotherapy;
WT: Wild-type.
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biopsy, namely circulating tumour DNA, to monitor the
clearance of pre-existing somatic mutations as a surrogate
end point for the efficacy of moAbs.
We think that in this field of research, the most interesting
area is represented by the finding of predictive biomarkers to
select those patients with higher probability to respond to
moAbs. These biomarkers need to be validated in large clini-
cal trials before their use in clinical practice. This procedure of
validation is possible for cancers with higher prevalence, that
is, colorectal cancer and breast cancer. However, this goal is
more difficult to achieve in other malignancies. So the
research in these cases would require much more time.
The identification of valid biomarkers for patients’ selec-
tion could be the proper solution to optimise the efficacy of
a new treatment and subsequently to limit the excessive cost
of a widespread prescription of expensive targeted drugs.
The knowledge of many biomarkers would lead to a personal-
ised cancer treatment. In the meantime, the research on the
mechanisms of resistance to moAbs would help to save
resources for useless treatment and to discover new drugs to
be delivered when the standard ones are no longer effective.
The realisation of these goals would yield a radical change in
the daily practice for most oncologists. For this reason, this
update could be a useful insight in what is coming in their
activity for next years.
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